Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2022, 31(5):311-319

Preventing and treating anthracycline cardiotoxicity

Sokol J1, Nehaj F2, 3, Chudej J1, Lisá L1, Lineková Ľ1, Staško J1
1 Klinika hematológie a transfuziológie, Jesseniova lekárska fakulta v Martine, Univerzita Komenského v Bratislave
2 Oddelenie arytmológie a kardiostimulácie, Národný ústav srdcových a cievnych chorôb, a. s., Bratislava
3 Klinika kardiológie a angiológie, Slovenská zdravotnícka univerzita, Bratislava, Slovenská republika

Anthracycline chemotherapeutic agents are widely used in the treatment of hematological and solid tumors, working principally through DNA intercalation and topoisomerase II inhibition. Unfortunately, their use is limited by a cumulative dose-dependent cardiotoxicity. Despite more than five decades of research, the biological mechanisms underlying anthracycline cardiotoxicity are not completely understood. The mechanisms through which cardiotoxicity occurs are complex and diverse, ultimately leading to increased oxidative stress, mitochondrial dysfunction, and subsequent cellular apoptosis. In this review, we explore the potential mechanisms of anthracycline-associated cardiotoxicity, identifying high-risk cohorts and approaches to cardiovascular monitoring.

Keywords: anthracyclines; pathomechanism; prevention; therapy

Published: May 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sokol J, Nehaj F, Chudej J, Lisá L, Lineková Ľ, Staško J. Preventing and treating anthracycline cardiotoxicity. Cardiology Letters. 2022;31(5-6):311-319.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967;20:333-353. Go to original source...
    2. Arcamone F, Cassinelli G, Fantini G, et al. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol. Bioeng. 1968;11:1101-1110. Go to original source...
    3. Middleman E, Luce J, Frei E 3rd. Clinical trials with adriamycin. Cancer. 1971;28:844-850. Go to original source...
    4. Khouri MG, Douglas PS, Mackey JR, et al. Cancertherapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation. 2012;126:2749-2763. Go to original source...
    5. Sawicki KT, Sala V, Prever L, et al. Preventing and Treating anthracycline cardiotoxicity: New Insight. Annu. Rev. Pharmacol. Toxicol. 2021;61:22.1-22.24. Go to original source...
    6. Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydro-genase. J Biol Chem. 1986;261:3060-3067. Go to original source...
    7. Cole MP, Chaiswing L, Oberley TD, et al. The protective roles of nitric oxide and superoxide dismutase in Adriamycin-induced cardiotoxicity. Cardiovasc Res. 2006;69:186-197. Go to original source...
    8. Stansfeld A, Radia U, Goggin C, et al. Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients. Expert Opin Pharmacother. 2022; Epub ahead of print. Go to original source...
    9. Goormaghtigh E, Huart P, Praet M, et al. Structure of the Adriamycin-cardiolipin complex. Role in mitochondrial toxicity. Biophys Chem. 1990;35:247-257. Go to original source...
    10. Aryal B, Rao VA, Mukhopadhyay P. Deficiency in cardiolipin reduces doxorubicin-induced oxidative stress and mitochondrial damage in human B-lymphocytes. PLoS One. 2016; 11:0158376. Go to original source...
    11. Zheng M, Kang YM, Liu W, et al. Inhibition of cyclooxygenase-2 reduces hypothalamic excitation in rats with Adriamycininduced heart failure. PLoS One. 2012;7:48771. Go to original source...
    12. Mordente A, Minotti G, Martorana GE, et al. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. Biochem Pharmacol. 2003;66:989-998. Go to original source...
    13. Lyu YL, Kerrigan JE, Lin CP, et al. Topoisomerase IIβ-mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67:8839-8846. Go to original source...
    14. Cancer Drug Manual Drug Index. [online]. [cit. 2022-10-09]. Dostupné na: < http://www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-drug-manual>.
    15. Hilfiker-Kleiner D, Ardehali H, Fischmeister R, et al. Late onset heart failure after childhood chemotherapy. Eur. Heart J. 2019;40:798-800. Go to original source...
    16. Morris PG, Hudis CA. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: How worried should we be? 2010; J. Clin. Oncol. 28:3407-3410. Go to original source...
    17. Aleman BM, van den Belt-Dusebout AW, DeBruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878-1886. Go to original source...
    18. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 1979;91:710-717. Go to original source...
    19. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869-2879. Go to original source...
    20. Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. 2008. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J. Natl. Cancer Inst. 100:1058-1067. Go to original source...
    21. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long- term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11:950-961. Go to original source...
    22. Myrehaug S, Pintilie M, Yun L, et al. A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood. 2010;116:2237-2240. Go to original source...
    23. Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes - a report from the Children's Oncology Group. J. Clin. Oncol. 2012;30:1415-1421. Go to original source...
    24. Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation. 2019;140:31-41. Go to original source...
    25. Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur. Heart J. 2016;37:16711680. Go to original source...
    26. Avila MS, Ayub-Ferreira SM, deBarros Wanderley-MR Jr., et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY Trial. J. Am. Coll. Cardiol. 2018;71:2281-2290. Go to original source...
    27. Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J. Am. Coll. Cardiol. 2013;61:2355-2362. Go to original source...
    28. Huelsenbeck J, Henninger C, Schad A, et al. Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity. Cell Death Dis. 2011;2:e190. Go to original source...
    29. Seicean S, Seicean A, Plana JC, et al. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J. Am. Coll. Cardiol. 2012;60:2384-2390. Go to original source...
    30. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004;56:185-229. Go to original source...
    31. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-3237. Go to original source...
    32. Beavers CJ, Rodgers JE, Bagnola AJ, et al. Cardio-oncology drug interactions: a scientific statement from the American Heart Association. Circulation. 2022;145:e811-e838. Go to original source...
    33. Caspani F, Tralongo AC, Campiotti, et al. Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis. Intern Emerg Med. 2021; 16:477-86. Go to original source...
    34. Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer. 1990;65:870-873. Go to original source...
    35. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC), Eur Heart J, 2022;ehac244.
    36. Oikonomou EK, Kokkinidis DG, Kampaktsis PN, et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol. 2019;4:1007-1018. Go to original source...
    37. Michel L, Mincu RI, Mahabadi AA, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail. 2020;22:350-361. Go to original source...
    38. Lotrionte M, Biondi-Zoccai G, Abbate A, et al. Review and metaanalysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am. J. Cardiol. 2013;112:1980-1984. Go to original source...
    39. Marty M, Espie M, Llombart A, et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann. Oncol. 2013;17:614-622. Go to original source...
    40. Swain SM, Whaley FS, Gerber MC, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J. Clin. Oncol. 1997;15:1333-1340. Go to original source...
    41. Swain SM, Whaley FS, Gerber MC, et al Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. 1997;15:1318-1332. Go to original source...
    42. Shaikh F, Dupuis LL, Alexander S, et al. Cardioprotection and second malignant neoplasms associated with dexrazoxane in children receiving anthracycline chemotherapy: a systematic review and meta-analysis. J. Natl. Cancer Inst. 2016;108(4):djv357. Go to original source...
    43. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur. J. Heart Fail. 2017;19:9-42. Go to original source...
    44. Faktorová X, Luknár M, Zelinková Z, Horniaková L, Mikušková E, Šašov M, et al. Advanced heart failure and cardiac arrhythmia in a young adult survivor of childhood cancer. Vnitřní lékařství, 2022;68:22-E26. Go to original source...

    Return to the content